Related Experiment Video

Updated: Jul 8, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Current status of signal transduction modulators in the treatment of gynecologic malignancies

Shay Ashouri1, Agustin A Garcia

  • 1Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.

Current Treatment Options in Oncology
|January 16, 2008
PubMed

Insights

Platinum and paclitaxel improved gynecological tumor treatment. Signal transduction modulators, like bevacizumab, show promise for recurrent ovarian cancer, with ongoing trials for frontline therapy.

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Cancer Therapeutics

Background:

  • Platinum and paclitaxel have significantly improved outcomes for gynecological tumors.
  • Recurrent ovarian cancer remains a challenge with limited effective treatment options.

Purpose of the Study:

  • To evaluate the efficacy of signal transduction modulators in gynecological tumors.
  • To explore the role of angiogenesis inhibitors, specifically bevacizumab, in recurrent ovarian cancer.

Main Methods:

  • Review of preliminary data on signal transduction modulators.
  • Analysis of bevacizumab's potential in recurrent ovarian cancer treatment.
  • Consideration of ongoing phase III trials for bevacizumab in frontline therapy.

Main Results:

  • Signal transduction modulators, particularly anti-VEGF monoclonal antibodies like bevacizumab, demonstrate significant activity in recurrent ovarian cancer.
  • Bevacizumab is being investigated in combination with chemotherapy as a frontline treatment.

Conclusions:

  • Bevacizumab and other signal transduction modulators are promising for gynecological tumor management.
  • Further research is warranted to establish the role of these agents in various treatment settings.

Related Concept Videos

Signal Transduction: Overview01:26

Signal Transduction: Overview

Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...